10 Amendments of Marian-Jean MARINESCU related to 2021/2013(INI)
Amendment 89 #
Motion for a resolution
Recital C a (new)
Recital C a (new)
C a. whereas one of the 20 principles of the European Pillar of Social Rights, reinforced by the Porto declaration, establishes that everyone has the right to timely access to affordable, preventive and curative health care of good quality;
Amendment 141 #
Motion for a resolution
Paragraph 1 – point 1 (new)
Paragraph 1 – point 1 (new)
(1) Considers that equal access to medicines for all EU patients, in terms of affordability and accessibility should be one of the pillars of the revised Pharmaceutical Strategy, as the principles of putting patients at the centre of all health policies demands;
Amendment 157 #
Motion for a resolution
Paragraph 2
Paragraph 2
2. ConsiderStresses that investments in research has not been sufficient to meet the therapeuticshould prioritise the needs of patients and health systems and focus on the greatest unmet needs of patients with rare diseases, paediatric cancers and neurodegenerative diseases or to deal with antimicrobial resistance (AMR);
Amendment 223 #
Motion for a resolution
Paragraph 4 a (new)
Paragraph 4 a (new)
4 a. Calls on the Commission to start the process of defining unmet medical needs, under the coordination of EMA, in order to reach a commonly accepted definition that would help a better orientation of research needs and would avoid the use of various definitions of unmet medical needs for exorbitant pricing and marketing medicines at an early stage;
Amendment 232 #
Motion for a resolution
Paragraph 4 b (new)
Paragraph 4 b (new)
4 b. Calls on the Commission to take the first steps to enhance transparency of research and development costs of medicines and to introduce new conditions for research funds so as to increase access for patients;
Amendment 253 #
Motion for a resolution
Paragraph 5 a (new)
Paragraph 5 a (new)
5 a. Calls on the Commission to develop fair pricing model for essential medicines that would reflect the real cost of research and production, limit the expenditure on sales and medical information and would reward medicines with an added therapeutic value, assuring fairness towards patients, industry and health systems;
Amendment 314 #
Motion for a resolution
Paragraph 7 a (new)
Paragraph 7 a (new)
7 a. Considers it important that the Commission addresses the issue of legal parallel trade in order to prevent shortages due to exports caused by high differences in terms of prices of a medicine between Member States and calls on starting to consider the possibility of declaring medicines public goods;
Amendment 324 #
Motion for a resolution
Paragraph 8
Paragraph 8
8. Welcomes the fact that the Commission will launch a pilot project to better understand the root causes of the delayed arrival of medicines on the market; calls on the Commission to look at the huge differences across EU of the average number of days between approval of a medicine and the moment it is available to the patients and to propose new ways to speed up the regulatory process;further welcomes the fact that the Commission will continue to monitor mergers between pharmaceutical companies to avoid distortions of competition; stresses the need to reduce medicine approval times at national level and align them with European Medicines Agency (EMA) times, in order to ensure rapid and equal access to medicines for everyone in the EU;
Amendment 358 #
Motion for a resolution
Paragraph 10
Paragraph 10
10. Stresses the importance of new joint EU public procurement contracts by the Commission and the Member States, especially for emergency medicines and unmet therapeutic needs; research funding should focus on the objective of increasing patients innovative medicines;
Amendment 442 #
Motion for a resolution
Paragraph 12 a (new)
Paragraph 12 a (new)
12 a. Calls on the Commission to include in the EU Statistics on Income and Living Conditions (EU-SILC) data on self-reported lack of access to medicines, as so far access to medicines in not measured in the EU-SILC;